GLP-1 medications for PCOS and insulin resistance: what the evidence shows

No GLP-1 medication is FDA-approved to treat polycystic ovary syndrome. But for women with PCOS who also meet the criteria for weight management treatment, international guidelines now say GLP-1 drugs can be considered, and smaller trials suggest benefits for weight, insulin resistance and, in some studies, menstrual regularity. The evidence is promising and still incomplete.

If you have PCOS, you may have been told for years to "just lose weight" by people who don't seem to understand how hard insulin resistance makes that. GLP-1 medications are changing the conversation, but it is worth being clear about what they are approved for and what the research actually shows.

Why PCOS and insulin resistance go together

PCOS is diagnosed using a combination of irregular or absent ovulation, signs of higher androgen levels (such as acne, excess facial or body hair, or scalp hair thinning) and polycystic-appearing ovaries on ultrasound, after ruling out other causes. Many women with PCOS, whether or not they have obesity, have insulin resistance. Their bodies need more insulin to keep blood sugar normal, and higher insulin levels can drive the ovaries to make more androgens, which disrupts ovulation.

That cycle helps explain why PCOS is linked to a higher risk of prediabetes, type 2 diabetes, gestational diabetes and heart disease risk factors. It also explains why treatments that improve insulin sensitivity, including weight loss and metformin, have long been part of PCOS care.

What the evidence shows

The guideline position

The 2023 International Evidence-based Guideline for the Assessment and Management of PCOS, led by Monash University and endorsed by many professional societies, reviewed the data on anti-obesity medications in PCOS. It concluded that GLP-1 receptor agonists can be considered, in addition to active lifestyle intervention, for managing higher weight in adults with PCOS, as they would be in the general population. It also advised effective contraception while taking them.

PCOS-specific trials

Studies of GLP-1 drugs in women with PCOS have mostly been small and short, often enrolling dozens rather than thousands of participants. Many used liraglutide or exenatide rather than semaglutide or tirzepatide. Across these studies, researchers have reported:

• Weight loss, generally greater than with lifestyle changes or metformin alone.
• Improved markers of insulin resistance.
• Lower testosterone levels in some studies.
• More regular menstrual cycles in some studies.

Results have been inconsistent, and the studies were not large enough to say much about long-term outcomes or fertility. Larger trials with newer drugs are under way. Until those report, the strongest evidence comes from the big general weight-management trials, such as STEP-1 for semaglutide and SURMOUNT-1 for tirzepatide, which enrolled many women but were not designed to study PCOS.

What weight loss itself does in PCOS

Separately from any drug, research on PCOS has found that losing about 5% to 10% of body weight can improve cycle regularity, ovulation and metabolic markers for some women. A medication that makes that more achievable may help indirectly. Whether GLP-1s have additional effects on the ovaries beyond weight loss is still being studied.

Pregnancy planning

GLP-1 medications are not recommended during pregnancy. Animal studies raised concerns, and there is not enough human data to show they are safe. The Wegovy prescribing information advises stopping at least 2 months before a planned pregnancy because semaglutide stays in the body for weeks. If you become pregnant while taking a GLP-1, contact your prescriber promptly.

For women trying to conceive, a clinician may use a GLP-1 for a period before pregnancy to help with weight and metabolic health, then stop before trying. That plan should be made with your OB-GYN or fertility specialist, not on your own.

GLP-1s and metformin

Metformin is widely used in PCOS, often off-label, to improve insulin sensitivity and cycle regularity. It is generic, inexpensive and has a long safety record, including in early pregnancy in some situations. GLP-1s tend to produce more weight loss. Some clinicians use the two together. The choice depends on your goals, whether you are planning pregnancy, side effects, cost and coverage.

Who may be a candidate

Because no GLP-1 is approved for PCOS itself, prescribing is based on weight-management criteria. Wegovy and Zepbound are approved for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. Insulin resistance, prediabetes and type 2 diabetes count, as do high blood pressure and high cholesterol. Our article on GLP-1 eligibility goes into the details, and who should not take a GLP-1 covers the main exclusions.

Women with PCOS who don't meet these thresholds may still have insulin resistance and symptoms that deserve treatment. Other options exist, and a GLP-1 isn't the only answer. If eating has been difficult or you have a history of an eating disorder, which is more common in women with PCOS, say so at your evaluation.

Insurance

Coverage for a weight-management GLP-1 depends on your plan's rules for obesity medications, not on the PCOS diagnosis. Some plans that cover Ozempic or Mounjaro for type 2 diabetes will not cover them for PCOS without diabetes. See our article on insurance coverage for weight loss medication.

A whole-picture approach

PCOS involves hormones, metabolism, fertility, skin and mood, and it changes across life stages. A GLP-1 may help with some of that. It doesn't replace care for irregular bleeding, acne or excess hair growth, fertility planning, or screening for diabetes and heart disease risk. Our article on hormone health for women covers related issues.

If you have PCOS and want to know whether a GLP-1 fits your situation, our weight management program starts with a full history, including your cycle, pregnancy plans and medications. A clinician may conclude that another approach suits you better.

Questions patients ask us

Is any GLP-1 FDA-approved to treat PCOS?

No. Semaglutide, tirzepatide and other GLP-1 drugs are not FDA-approved for PCOS itself. When a woman with PCOS is prescribed one for weight management, it is because she meets the weight-management criteria, which include a BMI of 30 or higher, or 27 or higher with a weight-related condition such as insulin resistance or prediabetes.

What does the international PCOS guideline say about GLP-1s?

The 2023 International Evidence-based Guideline for PCOS, led by Monash University, says GLP-1 receptor agonists can be considered alongside lifestyle support for managing higher weight in adults with PCOS. It also recommends effective contraception while taking them, given limited safety data in pregnancy.

Can a GLP-1 help regulate my periods with PCOS?

Some small studies, mostly with older GLP-1 drugs such as liraglutide and exenatide, reported more regular cycles alongside weight loss. Results have been inconsistent, and large PCOS-specific trials with semaglutide or tirzepatide are still limited. Weight loss of about 5% to 10% has been linked to improved cycles in some women.

Do GLP-1s improve insulin resistance in PCOS?

Studies in women with PCOS have generally found improvements in insulin resistance markers on GLP-1 drugs, largely alongside weight loss. Whether there is an additional effect beyond weight loss is still being studied. Your clinician may track fasting glucose, A1C or other markers to see how you respond.

Can I get pregnant while taking a GLP-1 for PCOS?

Yes, and sometimes unexpectedly. As weight comes down and ovulation resumes, fertility can return before periods become regular. GLP-1s are not recommended in pregnancy, so reliable contraception matters if you do not want to conceive. If you become pregnant while taking one, contact your prescriber promptly.

How long before trying to conceive should I stop a GLP-1?

The Wegovy prescribing information advises stopping semaglutide at least 2 months before a planned pregnancy, because it stays in the body for weeks. Timing for other GLP-1s may differ. Make this plan with your OB-GYN or fertility specialist, who can weigh the benefits of weight loss before pregnancy against timing.

Does tirzepatide affect birth control pills?

Yes. Tirzepatide can reduce how well oral contraceptives are absorbed, particularly after starting and after each dose increase. The Zepbound label advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. Ask your clinician about your specific method.

Should I take metformin or a GLP-1 for PCOS?

It depends on your goals. Metformin is inexpensive, generic and has a long safety record, and it is widely used in PCOS for insulin resistance and cycle regularity. GLP-1s tend to produce more weight loss. Some clinicians use both. Pregnancy plans, side effects, cost and coverage all factor into the choice.

Will insurance cover a GLP-1 for PCOS?

Coverage usually depends on your plan's rules for weight-management drugs, not the PCOS diagnosis. Plans that cover Ozempic or Mounjaro for type 2 diabetes generally will not cover them for PCOS without diabetes. If your plan covers obesity medications, the standard BMI and comorbidity criteria will typically apply.

Can I take a GLP-1 for PCOS if my BMI is under 27?

The approved weight-management GLP-1s are not indicated below a BMI of 27. Many women with PCOS have insulin resistance at lower weights, and other treatments, including metformin, hormonal therapy and targeted care for acne or hair growth, may be more appropriate. A clinician can review the options with you.